For your appropriate patients with relapsed
or refractory multiple myeloma
Primary analysis of PFS conducted with a minimum follow-up of 9.1 months:
HR 0.54; 95% CI: 0.34, 0.86; P=0.0078 (primary endpoint)1*
EMPLICITI + Pd: DOUBLE THE EFFICACY vs Pd ALONE1
DOUBLE THE mPFS (PRIMARY ENDPOINT)
DOUBLE THE ORR (SECONDARY ENDPOINT)
A Phase 2, randomized, open-label clinical study of EMPLICITI with pomalidomide and dexamethasone (EPd) vs Pd alone in patients with multiple myeloma (EPd, n=60; Pd, n=57). Patients must have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and be refractory to the most recent therapy. Primary endpoint: PFS. Secondary endpoints: ORR and OS.1,2
SELECTED IMPORTANT SAFETY
EMPLICITI® (elotuzumab) with pomalidomide and dexamethasone is associated with Warnings and Precautions related to:
Infusion Reactions, Infections, Second Primary Malignancies, Hepatotoxicity, Interference with Determination of Complete Response, Pregnancy/Females and Males of Reproductive Potential, and Adverse Reactions.
Please see detailed Important Safety Information below.
CI, confidence interval; HR, hazard ratio; NE, not estimable; ORR, overall response rate; OS, overall survival; Pd, pomalidomide + dexamethasone;
PFS, progression-free survival.